CRNX

Management highlighted Palsonify's strong launch progress with 232 new patient enrollments in Q1 and $10.3 million net product revenue. They discussed expanding the prescriber base to 263 unique prescribers, growing patient access with improved reimbursement coverage (70% of patients reimbursed by end of Q1), and advancing Palsonify globally with EU approval, JNDA submission in Japan, and MAA submission in Brazil. The pipeline was also advanced with four major trials ongoing, and Atomelnin and other candidates showing promising results in clinical studies.

Management maintained guidance for 2026 GAAP operating expenses between $600 - $650 million and non-GAAP operating expenses between $480 - $520 million. They project existing cash and investments will fund operations into 2030, providing runway for Palsonify commercialization and pipeline advancements.

For the Palsonify product segment, in the first quarter of 2026, there were 232 additional patient enrollments and net product revenue of $10.3 million. Palsonify contributed $10.3 million out of total revenue of $10.7 million, representing a significant portion of the segment's financial performance.

Risks discussed include uncertainties associated with forward-looking statements, business execution risks, potential challenges in international market expansion, and uncertainties related to clinical trial outcomes and regulatory approvals.

Q: For Palsonify, what was the percent of naive patients in the first quarter?

A: Isabel clarified the 15% was specific to Q1, with messages resonating well and reframing ORAS as a first-line option; Q: What's the scope of CAH data coming end of year?

A: Alan mentioned CAH data from phase trials, with momentum in enrollments and positive investigator response; Q: How about form to paid conversion rate for Palsonify?

A: Isabel said 70% reimbursed, working on converting quick starts to reimbursed patients with good pace